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60 hours per year. Themedian number of PE hours for required courses was 16 and
the mean number of students enrolled annually was 117. Learning objectives and
covered topics obtained from syllabi and surveys varied among colleges/schools.
CONCLUSIONS: More US Colleges/Schools of Pharmacy required PE education
compared to the 2007 survey, and the number of hours and students in these
courses increased. Although the extent of PE education has increased, a large vari-
ation in the number of teaching hours and list of covered topics among the colleges
and schools demonstrates a lack of uniformity or standardization for this area.
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OBJECTIVES: Optimal allocation of resources in healthcare requires a solid re-
search and educational infrastructure, especially for a developing country like
Egypt. Previous research focusing on pharmacoeconomic education status inter-
nationally did not report any information about the Egyptian case. The purpose of
this study was to assess the existing state of undergraduate and postgraduate
pharmacoeconomics education in the Egyptian schools of pharmacy.METHODS:A
survey methodology was employed in which a previously published survey was
adapted and modified into a 15-item survey to suit our research purpose. The
survey was administered to the head of the department under which offers phar-
macoeconomic related topics or to the dean of the school if not offered. To ensure
a higher response rate, surveyswere administered via e-mail,mail, and face to face
when necessary. RESULTS:We attempted to reach all the schools of pharmacy in
Egypt (n23). We received usable responses from 13 schools of pharmacy (56.5%).
Only 4 schools were offering pharmacoeconomic education at the time of survey
completion with an average of 35 teaching hours per course (median 38.5 hrs).
Average estimated class size was 420 students (range: 280-600). Among the 4
schools offering pharmacoeconomics, only 1 faculty member was trained through
a formal PhD program. Two schools offered pharmacoeconomics education at the
graduate level. Methods of pharmacoeconomic analyses were the most commonly
taught topics. Out of the 13 schools of pharmacy, 9 schools expressed their interest to
teach a course fully dedicated to pharmacoeconomics in the near future (2-4 years).
CONCLUSIONS: Pharmacoeconomic education in Egypt is still in its infancy. Inter-
est was expressed by faculty members in integrating pharmacoeconomics into
pharmacy education. Lack of subject area experts might be a major barrier in such
adoption. There exists a unique opportunity for well-trained individuals to fill this
gap.
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OBJECTIVES: The objective of this research was to validate with provincial drug
plan managers if the guidelines for conducting pharmaceutical budget impact
analyses (BIA) in Canada, published by the PatentedMedicines Prices Review Board
(PMPRB) in 2007, meet their needs. METHODS: A survey entitled Budget Impact
Analysis Requirements by Canadian Provincial Drug Plans was developed and sent by
email to all provincial drug plan managers, at the exception of Quebec. The survey
consisted in 14 questions that take approximately twenty minutes to complete.
RESULTS: The participation rate of the provinces was of 55.6%. In 60% of the par-
ticipating provinces, the person that completed the questionnaire was the drug
plan manager, therefore a reliable source of information. Forty percent of the par-
ticipating provinces prefer that the market size for the BIA to be estimated using a
population data-based model versus a claims data-based model, 40% prefer both
models, and 20% have no specific preference. The guidelines developed by PMPRB
recommend the use of a population data-based model. 100% of the participating
provinces agree that if a comparator will lose its patent over the time horizon, it
should be taken in consideration in the BIA. The guidelines, however, do not pro-
vide any recommendations regarding the inclusion of generic products. Accurate
drug cost reporting is an important component of the BIA. The dollar or percentage
value for wholesaler mark-up, pharmacy mark-up, inventory allowance and dis-
pensing fees provided by 80% participating provinces do not match those recom-
mended by the BIA guidelines. CONCLUSIONS:Overall, the guidelines for conduct-
ing pharmaceutical BIA in Canada, published by PMPRB in 2007, meet the needs of
provincial drug planmanagers. However, they should be updated in order to reflect
the changes that have occurred in the pharmaceutical industry, especially those
around the Canadian price of generics.
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OBJECTIVES: The main role of AOTM is to prepare recommendations on financing
all medical technologies from public funds for the Minister of Health. For all new
health technologies entering market full pharmacoeconomic evaluations are re-
quired before reimbursement decisions are taken. The aim of the present analysis
was to identify what was the impact of low efficacy on AOTM negative recommen-
dations issued for innovative drugs. METHODS: All recommendations issued by
AOTM in 2011 were reviewed and analyzed.We distinguished those regarding only
innovative drugs (other recommendations were excluded) and identified the rea-
son for negative statement. RESULTS: In 2011 AOTM issued 111 recommendations
for medical technologies and . services. 85 (76%) were connected with new medi-
cines (innovative drugs). The full positive decisions were given for 51 drugs (60%).
For 16 of 85 (19%) drugs AOTM issued conditional recommendations (with restric-
tion related with reducing the cost- effectiveness outcomes). Negative recommen-
dations were given for reimbursement to 18 of 85 (21%) of innovative drug submis-
sions. In one case budget impact and the corresponding high prices were
emphasized as a main reason of negative recommendations. Also only in one case
the reason was connected with drug safety issues, while in 16 cases with insuffi-
cient evidence of efficacy CONCLUSIONS: Low efficacy of appraised innovative
drugs was a key factor of negative recommendations published by AOTM in 2011.
Neither cost-effectiveness nor costs, safety and budget impact were significant
arguments in negative recommendations of AOTM.
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OBJECTIVES: The VA Center for Medication Safety has developed a data-extract
driven, web-based, user-interface application for a medication utilization evalua-
tion tracker (MUET). MUET identifies at-risk patients as well as records, stores, and
tracks clinical interventions in a centralized interactive VA database accessible to
all 152 VA Medical Centers (VAMCs). The objective of this study is to describe the
impact of a MUET tool designed to address the safety and monitoring needs of
at-risk patients on erythropoiesis stimulating agents (ESAs) and to enable inter-
ventions to be tracked in a centralized database. METHODS: Data are extracted
from the VA PBM prescription and laboratory databases each month, and poten-
tially at-risk patients on ESA therapy are loaded into the MUET tool. Four trigger
groups indicating quality of care issues are identified: No Hgb, Hgb  12 and  13
g/dL, Hgb  13 g/dL, and Hgb  9 g/dL with no recent ferritin assessment. Upon
log-in toMUET, clinicians are prompted to address the safety needs of each patient
by selecting from a list of interventions that are recorded and tracked over time.
RESULTS: Approximately 2.5 years after ESA MUET initiation, chi-square tests
showed decreases in patients without Hgb labs (11.4% to 3.0%, p0.0001); in pa-
tients with Hgb  12 g/dL and  13 g/dL (12.7% - 7.3%, p0.0001); and in patients
with Hgb  13 g/dL (5.7% - 3.0%, p0.0001). A non-significant decrease was ob-
served in patients with Hgb 9 g/dL andwithout a ferritin assessment (3.1% - 2.8%,
p0.3960). CONCLUSIONS: The ESA MUET is a real-time web application tool ac-
cessible by all medical centers within the VA health care network to identify and
intervene on patients at potential risk. Data trends demonstrate significant im-
provements in 3 out of 4 ESA risk groups.
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OBJECTIVES: As technological advances are becoming common in hospitals, its
impact on work efficiency also needs to be evaluated. The objective of this study
was to evaluate the long term effect of a bedside bar-coded medication adminis-
tration system and a medication dispensing system on the time taken for the
medication administration process. METHODS: A prospective cohort study was
conducted to compare medication administration time before and after the inter-
vention in an intensive care unit in a large tertiary hospital using a pre-validated
time and motion observation instrument. Bedside bar-coded medication adminis-
tration system was implemented in July 2008 and the medication dispensing sys-
tem was implemented on November 2009. Pre-intervention data were collected in
April-May 2008 and post-intervention data were collected in June-July 2010. Mean
duration of time dedicated to medication administration activity was compared.
Multivariate analysis of covariance (MANCOVA) was conducted to assess the effect
of the intervention by controlling factors such as patients’ age, gender, body-
weight and length of ICU stay, number of drugs administered, and number of
nurses involved. RESULTS: A total of 101 pre-intervention and 109 post-interven-
tion medication administrations were recorded. Mean ( SD) overall medication
administration time was increased from 313.3 (224.3) seconds during pre-inter-
vention period to 613.7 (348.7) seconds during the post-intervention period.
Nurses spent significantly (p0.05) more time on direct patient care activity (pre:
47.460.6 seconds, post: 89.178.5 seconds) and less time on indirect patient care
activity (pre: 13.0 25.8 seconds, post: 6.1 13.8 seconds, p0.05) during post-
intervention period. CONCLUSIONS: Health technology intervention improved
time spent on direct patient care activity and reduced time spent on indirect pa-
tient care activity after implementation of bedside bar-code technology and amed-
ication dispensing system.
PHP77
TECHNOLOGICAL INTERVENTION: NURSES’ PERCEPTION REGARDING
PERFORMANCE OBSTACLES AND EASE OF WORK
Hatfield MD1, Dwibedi N1, Frost CP2, Sansgiry SS1
1University of Houston, Houston, TX, USA, 2St. Luke’s Episcopal Hospital, Houston, TX, USA
OBJECTIVES: To evaluate perception of nurses regarding performance obstacles
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